In the CCL4 model of liver fibrosis, serum BGM was elevated after 16 and 20 weeks of treatment compared with controls and these data are in agreement with the literature stating that biglycan is highly deposited in sites affected by fibrosis [21], where MMP levels are elevated and unbalanced during fibrogenesis [30]. The gene discussed is BGN; the disease is Hepatic fibrosis.